# NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC

> **NCT07318636** · PHASE1 · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital of Guangzhou Medical University** · enrollment: 10 (estimated)

## Conditions studied

- Resectable Non-small Cell Lung Cancer

## Interventions

- **DRUG:** PD-1 antibody
- **BIOLOGICAL:** NK010

## Key facts

- **NCT ID:** NCT07318636
- **Lead sponsor:** The First Affiliated Hospital of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-20
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07318636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07318636, "NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07318636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*